Literature DB >> 10639639

Low-Molecular-Weight Heparin in the Initial Treatment of Proximal Deep Vein Thrombosis.

.   

Abstract

Intravenous unfractionated heparin followed by oral warfarin is the current standard of care for the treatment of acute venous thrombosis. More recently, several low-molecular-weight heparin preparations have been shown to be as effective and safe as unfractionated heparin for the initial therapy of acute proximal vein thrombosis. These drugs have a number of advantages over unfractionated heparin, and will undoubtedly replace the current standard for the initial treatment of venous thromboembolism.

Entities:  

Year:  1997        PMID: 10639639     DOI: 10.1023/a:1008841215025

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  11 in total

1.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

Review 2.  Antithrombotic therapy for venous thromboembolic disease.

Authors:  T M Hyers; R D Hull; J G Weg
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 3.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; R Raschke; T E Warkentin; J E Dalen; D Deykin; L Poller
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

4.  The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.

Authors:  R A Raschke; B M Reilly; J R Guidry; J R Fontana; S Srinivas
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

5.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.

Authors:  G Simonneau; B Charbonnier; H Decousus; B Planchon; J Ninet; P Sie; M Silsiguen; S Combe
Journal:  Arch Intern Med       Date:  1993-07-12

6.  Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

Authors:  D P Brandjes; H Heijboer; H R Büller; M de Rijk; H Jagt; J W ten Cate
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

7.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Authors:  P Prandoni; A W Lensing; H R Büller; M Carta; A Cogo; M Vigo; D Casara; A Ruol; J W ten Cate
Journal:  Lancet       Date:  1992-02-22       Impact factor: 79.321

8.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.